Allergic Rhinitis - Epidemiology Forecast to 2023, Now Available on ASDReports

Friday 3 October 2014, Amsterdam

Allergic rhinitis is a chronic respiratory disease characterized by inflammation of the nasal cavity and affects people of all ages. The main symptoms of allergic rhinitis are sneezing, nasal itching, blocked or runny nose and sore throat (NHS, 2012; WHO, 2013). Research suggests that a combination of genetic factors such as family history of allergic rhinitis and environmental factors such as exposure to allergens, including smoke, dust, pollen, insects, molds, or animal dander, may increase the risk for developing allergic rhinitis (NHS, 2012; WHO, 2013). In the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan), the prevalence of self-reported allergic rhinitis ranges from 13.7% in men and 14.3% in women in the US to 35.1% in men and 39.3% in women in Japan (Bauchau and Durham, 2004; Konno et al., 2012; Nathan et al., 1997; Ozdoganoglu and Songu, 2012). According to the World Health Organization (WHO), an estimated 400 million people worldwide were affected with allergic rhinitis during 1996–2006 (WHO, 2007).

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for allergic rhinitis in the 7MM. The report also includes a 10-year epidemiological forecast of the total prevalent cases of allergic rhinitis in these markets, segmented by sex and age (ages ≥18 years). To forecast the total prevalent cases of allergic rhinitis in the 7MM, Epidemiologists selected only nationally representative studies that provided the total prevalence of allergic rhinitis using uniform diagnostic criteria based on the self-reported prevalence of allergic rhinitis. Additionally,  epidemiologists provide the total prevalent cases of allergic rhinitis segmented by the etiological type of allergic rhinitis (seasonal, perennial, and both), as well as by the severity of allergic rhinitis (mild, moderate, and severe) in these markets (ARIA, 2007; Bousquet and Cauwenberge, 2002; Bousquet et al., 2008a; WHO, 2013). In addition, epidemiologists provide the population of allergic rhinitis cases segmented by sensitization to specific allergens in the six major markets (6MM) (France, Germany, Italy, Spain, UK and Japan). 

According to epidemiological forecast, the total prevalent cases of allergic rhinitis in the 7MM will increase from 123,273,876 total prevalent cases in 2013 to 125,427,387 total prevalent cases in 2023, at an annual growth rate (AGR) of 0.17% during the forecast period. In 2023, the US will have the highest number of the total prevalent cases of allergic rhinitis with 39,031,365 total prevalent cases, followed by Japan with 36,602,227 total prevalent cases. Because epidemiologists applied a constant total prevalence in each of the 7MM, the marginal increase in the total prevalent cases of allergic rhinitis in the 7MM is attributed

o the changes in the population demographics in the 7MM rather than to an increase in the total prevalence of allergic rhinitis.